{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T08:11:07Z","timestamp":1789891867291,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T00:00:00Z","timestamp":1289865600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Myelodysplastic syndrome (MDS) may be induced by certain mutagenic environmental or chemotherapeutic toxins; however, the role of susceptibility genes remains unclear. The G\/G genotype of the single-nucleotide polymorphism (SNP) rs1617640 in the erythropoietin (<jats:italic>EPO<\/jats:italic>) promoter has been shown to be associated with decreased EPO expression. We examined the association of rs1617640 genotype with MDS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We genotyped the EPO rS1617640 SNP in 189 patients with MDS, 257 with acute myeloid leukemia (AML), 106 with acute lymphoblastic leukemia, 97 with chronic lymphocytic leukemia, 353 with chronic myeloid leukemia, and 95 healthy controls.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The G\/G genotype was significantly more common in MDS patients (47\/187; 25.1%) than in controls (6\/95; 6.3%) or in patients with other leukemias (101\/813; 12.4%) (all <jats:italic>P<\/jats:italic> &lt; 0.001). Individuals with the G\/G genotype were more likely than those with other genotypes to have MDS (odd ratio = 4.98; 95% CI = 2.04-12.13). Clinical and follow up data were available for 112 MDS patients and 186 AML patients. There was no correlation between EPO promoter genotype and response to therapy or overall survival in MDS or AML. In the MDS group, the GG genotype was significantly associated with shorter complete remission duration, as compared with the TT genotype (<jats:italic>P<\/jats:italic> = 0.03). Time to neutrophils recovery after therapy was significantly longer in MDS patients with the G\/G genotype (<jats:italic>P<\/jats:italic> = 0.02).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These findings suggest a strong association between the rs1617640 G\/G genotype and MDS. Further studies are warranted to investigate the utility of screening for this marker in individuals exposed to environmental toxins or chemotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2350-11-163","type":"journal-article","created":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T07:16:38Z","timestamp":1289891798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome"],"prefix":"10.1186","volume":"11","author":[{"given":"Wanlong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber C","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hsiung","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Caporaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,16]]},"reference":[{"issue":"3","key":"724_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ajh.21352","volume":"84","author":"MT Kasner","year":"1997","unstructured":"Kasner MT, Luger SM: Update on the therapy for myelodysplastic syndrome. Am J Hematol. 1997, 84 (3): 177-186. 10.1002\/ajh.21352.","journal-title":"Am J Hematol"},{"issue":"4","key":"724_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","volume":"35","author":"LA Godley","year":"2008","unstructured":"Godley LA, Larson RA: Therapy-related myeloid leukemia. Semin Oncol. 2008, 35 (4): 418-429. 10.1053\/j.seminoncol.2008.04.012.","journal-title":"Semin Oncol"},{"issue":"8","key":"724_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10552-005-2301-3","volume":"16","author":"A Descatha","year":"2005","unstructured":"Descatha A, Jenabian A, Conso F, Ameille J: Occupational exposures and haematological malignancies: overview on human recent data. Cancer Causes Control. 2005, 16 (8): 939-953. 10.1007\/s10552-005-2301-3.","journal-title":"Cancer Causes Control"},{"issue":"12","key":"724_CR4","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.5858\/2007-131-1789-PITATA","volume":"131","author":"MP Powers","year":"2007","unstructured":"Powers MP, Nishino H, Luo Y, Raza A, Vanguri A, Rice L, Zu Y, Chang CC: Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med. 2007, 131 (12): 1789-1793.","journal-title":"Arch Pathol Lab Med"},{"issue":"3-4","key":"724_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1556\/AMicr.52.2005.3-4.15","volume":"52","author":"Z Gyulai","year":"2005","unstructured":"Gyulai Z, Balog A, Borb\u00e9nyi Z, M\u00e1ndi Y: Genetic polymorphisms in patients with myelodysplastic syndrome. Acta Microbiol Immunol Hung. 2005, 52 (3-4): 463-475. 10.1556\/AMicr.52.2005.3-4.15.","journal-title":"Acta Microbiol Immunol Hung"},{"key":"724_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1471-2407-9-140","volume":"9","author":"K Broberg","year":"2009","unstructured":"Broberg K, Huynh E, Schl\u00e4wicke Engstr\u00f6m K, Bj\u00f6rk J, Albin M, Ingvar C, Olss\u00f6n H, H\u00f6glund M: Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study. BMC Cancer. 2009, 9: 140-10.1186\/1471-2407-9-140.","journal-title":"BMC Cancer"},{"issue":"19","key":"724_CR7","doi-asserted-by":"publisher","first-page":"6998","DOI":"10.1073\/pnas.0800454105","volume":"105","author":"Z Tong","year":"2008","unstructured":"Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X, Hau VS, Kaminoh Y, Harmon J, Pearson E, et al: Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA. 2008, 105 (19): 6998-7003. 10.1073\/pnas.0800454105.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"724_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/blood-2007-03-079681","volume":"111","author":"D Metcalf","year":"2008","unstructured":"Metcalf D: Hematopoietic cytokines. Blood. 2008, 111 (2): 485-491. 10.1182\/blood-2007-03-079681.","journal-title":"Blood"},{"issue":"9","key":"724_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.exphem.2009.05.010","volume":"37","author":"W Fried","year":"2009","unstructured":"Fried W: Erythropoietin and erythropoiesis. Exp Hematol. 2009, 37 (9): 1007-1015. 10.1016\/j.exphem.2009.05.010.","journal-title":"Exp Hematol"},{"issue":"5","key":"724_CR10","first-page":"863","volume":"99","author":"M Wadhwa","year":"2008","unstructured":"Wadhwa M, Thorpe R: Haematopoietic growth factors and their therapeutic use. Throm Haemost. 2008, 99 (5): 863-873.","journal-title":"Throm Haemost"},{"issue":"3","key":"724_CR11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.tcb.2005.01.007","volume":"15","author":"TD Richmond","year":"2005","unstructured":"Richmond TD, Chohan M, Barber DL: Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol. 2005, 15 (3): 146-155. 10.1016\/j.tcb.2005.01.007.","journal-title":"Trends Cell Biol"},{"issue":"3","key":"724_CR12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V82.3.737.737","volume":"82","author":"RS Negrin","year":"1993","unstructured":"Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL: Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood. 1993, 82 (3): 737-743.","journal-title":"Blood"},{"issue":"10","key":"724_CR13","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076","volume":"87","author":"RS Negrin","year":"1996","unstructured":"Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996, 87 (10): 4076-4081.","journal-title":"Blood"},{"issue":"Suppl 1","key":"724_CR14","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.3816\/CLM.2003.s.007","volume":"4","author":"RS Stein","year":"2003","unstructured":"Stein RS: The role of erythropoietin in the anemia of myelodysplastic syndrome. Clin Lymphoma. 2003, 4 (Suppl 1): S36-40. 10.3816\/CLM.2003.s.007.","journal-title":"Clin Lymphoma"},{"issue":"21","key":"724_CR15","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","volume":"26","author":"M J\u00e4dersten","year":"2008","unstructured":"J\u00e4dersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, Pascutto C, Porwit A, Cazzola M, Hellstr\u00f6m-Lindberg E: Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008, 26 (21): 3607-13. 10.1200\/JCO.2007.15.4906.","journal-title":"J Clin Oncol"},{"issue":"2","key":"724_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","volume":"111","author":"S Park","year":"2008","unstructured":"Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mah\u00e9 B, Ferrant A, Ravoet C, Escoffre-Barbe M, Ad\u00e8s L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F, GFM group (Groupe Francophone des My\u00e9lodysplasies): Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008, 111 (2): 574-82. 10.1182\/blood-2007-06-096370.","journal-title":"Blood"},{"issue":"12","key":"724_CR17","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","volume":"114","author":"PL Greenberg","year":"2009","unstructured":"Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM: Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009, 114 (12): 2393-400. 10.1182\/blood-2009-03-211797.","journal-title":"Blood"},{"issue":"9","key":"724_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.leukres.2008.02.022","volume":"32","author":"P Valent","year":"2008","unstructured":"Valent P: Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports. Leuk Res. 2008, 32 (9): 1333-7. 10.1016\/j.leukres.2008.02.022.","journal-title":"Leuk Res"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-11-163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2350-11-163\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-11-163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-11-163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:11:40Z","timestamp":1630469500000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/1471-2350-11-163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,16]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["724"],"URL":"https:\/\/doi.org\/10.1186\/1471-2350-11-163","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,16]]},"assertion":[{"value":"10 March 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"163"}}